<DOC>
	<DOCNO>NCT01991340</DOCNO>
	<brief_summary>This observational study ass safety Herceptin ( trastuzumab ) patient HER2-positive breast cancer routine clinical practice . Eligible patient follow 4 year .</brief_summary>
	<brief_title>H.E.R.O.S . Study : An Observational Study Cardiac Safety Herceptin ( Trastuzumab ) Patients With HER2-Positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histologically confirm HER2positive breast cancer Eligible receive Herceptin per Summary Product Characteristics Contraindications accord Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>